



Established by: Dr Bridget S Wilkins

On behalf of the ECMC

Cellular Molecular Pathology Network Group

Chairperson: Dr Karin Oien

Cellular and Molecular Pathology are Vitrally Important for Cancer Patients

- Almost every cancer patient requires a histological or cytological test from pathology for initial diagnosis
- Many additional clinically suspect lesions are confirmed by such tests not to be malignant
- There is a rapidly increasing need for innovative testing to assess prognosis and to support stratified/ personalised medicine approaches
- Pathology needs to integrate new technologies and ‘omics’ into diagnostic assessments of cancer

The Future is Molecular (and the Future is Digital)




Cellular Pathology needs to modernise and innovate –
and to keep doing so at pace


Where are the innovators?

Decline in academic pathology is greatest of all clinical specialities

All academic posts
in the UK 2000-2012




Academic pathology posts
in the UK 2000-2012



Delving deeper into Cellular Pathology

Decline in academic Cellular Pathology appears to be worst affected


Self-declared academic cellular pathology posts 2015



Delving deeper into Cellular Pathology

Variation in academic cellular pathology posts across centres


Self-declared academic Cellular Pathology posts 2015 by centre




Delving deeper into Cellular Pathology

Variation in academic Cellular Pathology posts across centres

Programmed Activities (PA) for research against Pathology Dept total PAs 2015




Where are the Resources?




Is there research desire?

Survey on research attitudes and access within the Cellular Pathology community

Within your role as a consultant cellular pathologist, do you wish to undertake research? - Research Attitudes Survey 2015



Within your role as a consultant cellular pathologist, do you wish to supervise/mentor others undertaking research? - Research Attitudes Survey 2015





What are the barriers?


Survey on research attitudes and access within the Cellular Pathology community

Presence of which three factors in your job plan and work environment are most favourable to your undertaking research?


Absence/limitation of which three factors in your job plan and work environment are least favourable to your undertaking research?




What do we need for the future in Cellular (Molecular) Pathology research?




CM-Path Structure




CM-Path Structure and Relationships




Workstream 1 – Skills & Capacity




Workstream 2 – Clinical Trials




Workstream 3 – Discovery




Workstream 4 – Technology & Informatics



Cross-Cutting Themes




Priorities for first 6 months



Establishing Executive Group & WSs

Chairperson:	Dr Karin Oien
Workstream 1 co-lead:	Professor Manuel Salto-Tellez
Workstream 1 co-lead:	Professor Louise Jones
Workstream 2 lead:	Dr Alex Freeman
workstream 3 lead:	Professor Gareth Thomas
Workstream 4 lead:	Dr Stefan Dojcinov
RCPATH representative:	Dr Bridget Wilkins
PathSoc representative:	To be confirmed
Funder representative:	Dr Rowena Sharpe (CRUK)
Funder representative:	Dr Angharad Kerr (NHS)
Patient representatives:	To be confirmed
Programme manager:	Jessica Lee
NCRI strategic planning:	Dr Susan Kohlhaas

Key Stakeholders




Launch and objectives

Monday 6 June 2016

- Introduction to CM-Path
- Introduction to NCRI
- Lessons from CT-Rad
- Team-building
- Workstream breakout sessions & reporting back
- Leading to early SMART objectives
- Establishing clear roles and responsibilities, accountability and expectations, especially for “cross-cutting themes”



CM-Path: Where we should see activity in 5 years



- Legacy



Thank you!

